Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273)

D. J. Inwards, P. A. Fishkin, B. R. Laplant, M. T. Drake, P. J. Kurtin, D. A. Nikcevich, D. B. Wender, B. S. Lair, T. E. Witzig

Research output: Contribution to journalComment/debate

Abstract

The following funding statement was missing from the original manuscript: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Also supported in part by funds from Wyeth Pharmaceuticals. Wyeth was subsequently purchased by Pfizer Pharmaceuticals. This has now been amended in the online version.

Original languageEnglish (US)
Number of pages1
JournalAnnals of Oncology
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Erratum: Phase I trial of rituximab, cladribine, and temsirolimus (rct) for initial therapy of mantle cell lymphoma (Annals of Oncology (2014) 25 (2020-2024) DOI: 10.1093/annonc/mdu273)'. Together they form a unique fingerprint.

  • Cite this